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Ras signalling is required for inactivation of the tumour
suppressor pRb cell-cycle control protein
Sibylle Mittnacht, Hugh Paterson, Michael F. Olson and Christopher J. Marshall
Ras proteins act as molecular switches, responding to
signals by entering the active GTP-bound, rather than the
inactive GDP-bound, state. The inhibition of normal Ras
proteins by microinjection of neutralizing antibody or
expression of dominant-negative mutants has shown
that Ras signalling is required for growth factors to
stimulate DNA synthesis [1,2], but the link between Ras
and the cell-cycle machinery is not clear. Regulation of
the phosphorylation state of the retinoblastoma protein
(pRb), the product of the tumour suppressor gene Rb, is
a key event in the progression of cells from G1 phase
into S phase. In growth-arrested or early G1 cells, pRb is
hypophosphorylated and binds to transcription factors of
the E2F family [3]. These pRb–E2F complexes act to
suppress gene transcription required for entry into DNA
synthesis either by preventing E2F from stimulating
transcription or by actively repressing transcription [4].
During G1, cyclin-dependent kinases (CDKs) become
activated and phosphorylate pRb at multiple sites,
leading to the dissolution of pRb–E2F complexes and
gene transcription [5]. Here, we have tested the
hypothesis that Ras signalling is required for the
inactivation of pRb. A neutralizing antibody directed
against p21Ras was microinjected into cells derived from
mutant mouse embryos that lack Rb or CDK inhibitors
(CDKIs). Cells without pRb or the p16 CDKI were more
resistant to the inhibitory effects of the anti-Ras
antibody. DNA synthesis in some tumour cell lines was
completely resistant to the anti-Ras injection, indicating
that p21Ras is required for pRb inactivation but also has
other functions in cell-cycle progression.
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Results and discussion
The Ras-neutralizing monoclonal antibody Y13-259 [6]
has been shown in a variety of systems to block Ras-
dependent signalling, probably by preventing the forma-
tion of a complex between p21Ras–GTP and Ras
effectors [1,7]. To determine whether Ras signalling was
required for the inactivation of Rb, we injected Y13-259
into mouse embryo fibroblasts (MEFs) derived from
homozygous mouse embryos that lack Rb as a result of
germline manipulation [8]. As a control for effects of the
microinjection procedure, MEFs were injected with rat
immunoglobulin. Asynchronous growing cultures were
Table 1
Deletion of pRb reduces sensitivity to inhibition of DNA
synthesis by microinjection of Ras-neutralizing antibody.
Cells Experiment % Injected cells % Inhibition
(vector) in DNA synthesis of DNA synthesis
Y13-259 IgG Y13-259/IgG Mean
MEF Rb+/– 1† 4.4 77.8 94.4
2* 8.0 80.3 90.0
3 13.5 71.0 81.0 88.5
MEF Rb–/– 1† 51.5 95.0 45.8
2* 51.7 69.0 25.0
3 51.5 78.0 33.9 34.9
MEF Rb–/–
(puro) 1 18.2 38.0 50.0
(puro-HsRb) 6.3 39.0 84.9
(puro) 2‡ 30.7 51.0 46.0
(puro-HsRb) 0.7 53.0 98.0
MEF cells (1–2 × 105) were seeded in a 60 mm dish in Dulbecco’s
modified Eagle’s medium (DMEM) with 10% serum. The next day, they
were injected using a Zeiss-Eppendorf cell microinjection apparatus with
rat monoclonal anti-Ras antibody Y13-259 (purified on protein G
sepharose) or rat immunoglobulin G (IgG; ChromPure, Jackson
ImmunoResearch). Cells were returned to the incubator and cultured for
21 h (or 16 h*) before BrdU (Amersham UK) was added and the
incubation continued for a further 10 h (or 18 h†). Cells were then fixed
and stained for incorporated BrdU using a mouse monoclonal antibody
against BrdU (Boehringer) followed by FITC-coupled donkey antisera
specific for mouse IgG (Jackson ImmunoResearch). Injected cells were
identified by counterstaining with TRITC-coupled donkey antisera
specific for rat IgG (Jackson ImmunoResearch). Two-colour
immunofluorescence was visualized with an MRC 600 confocal
microscope (BioRad). Between 150–350 injected cells were scored for
each experiment. To introduce wild-type Rb, the vector pBabe-puro-
HsRb was constructed by subcloning the cDNA for human Rb [23] via
BamHI restriction sites into pBabe-puro [24]. Retrovirus stocks were
produced by transfecting pBabe-puro-HsRb into BOSC 23, as
described [25]. Subconfluent cultures of Rb–/– MEFs were then infected
with pBabe-puro-HsRb retrovirus stock or pBabe-puro retrovirus stock
and transduced cells selected by incubation in DMEM / 10% serum
containing 6 mg ml–1 puromycin. After 7–8 days, cultures were confluent
and used for microinjection as described above. Expression of human Rb
was detected by indirect immunofluorescence using the pRb-specific
antibody 245 (Pharmingen). Statistical analysis was performed with
Student’s t-test with arc–sin transformation of data; this gives
significance levels of p < 0.001 for Y13-259 injections into Rb–/– and
Rb+/– cells, and p < 0.05 for the comparison of Y13-259 and control
IgG injection into Rb–/– cells.
microinjected and, at 16–21 hours post-injection, cells
were labelled for 10 or 18 hours with bromodeoxyuridine
(BrdU) to detect DNA synthesis. Isogenic controls were
provided by cultures of cells derived from Rb+/– or Rb+/+
littermate embryos. Table 1 shows that the injection of
Y13-259 strongly inhibited DNA synthesis in Rb+/– MEFs
(mean inhibition 88.5%), whereas Rb–/– MEFs were sig-
nificantly less inhibited (mean inhibition 34.9%; t-test,
p < 0.001). Note, however, that Y13-259 injection still
inhibited Rb–/– cells compared with control cells injected
with rat immunoglobulin (p < 0.05).
To extend and confirm these effects, we examined
whether the introduction of wild-type Rb into Rb–/–
MEFs would restore sensitivity to Y13-259 injection.
Rb–/– MEFs were infected with a retrovirus vector
(pBabe-puro-HsRb) carrying the human Rb gene and the
gene for puromycin resistance, or with the empty vector
(pBabe-puro), and puromycin-resistant cells were
selected. More than 95% of the puromycin-resistant cells
infected with pBabe-puro-HsRb expressed human pRB
(Fig. 1a,b). Figure 1d and Table 1 show that introduction
of wild-type Rb restores complete sensitivity to inhibition
of DNA synthesis by injection of Y13-259 (inhibition
84–98%). The injection of Y13-259 into puromycin-resis-
tant Rb–/– MEFs infected with the empty vector inhibited
DNA synthesis by 46–50% (Fig. 1c and Table 1). The
experiments presented in Table 1 therefore show that
cells lacking pRb have a reduced requirement for p21Ras
signalling, suggesting that the inactivation of pRb is one
of the functions of p21Ras signalling that promotes cell
proliferation.
The ability of pRb to suppress entry into DNA synthesis is
overcome through its phosphorylation by G1 CDKs [9,10].
The activity of these kinases has been shown to be
regulated at the level of transcriptional activation of D- and
E-type cyclins or by CDKIs [11,12]. Two general classes of
CDKIs have been identified: the p16 family, members of
which bind directly to CDK4/CDK6 and specifically
regulate cyclin-D-dependent kinases; and the p21 family,
members of which bind to CDK–cyclin complexes and
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Figure 1
(a,b) Immunostaining for human wild-type pRb
in Rb–/– MEFs infected with (a) pBabe-puro
empty vector or (b) pBabe-puro-HsRb. (c,d)
DNA synthesis following the microinjection of
Y13-259 into (c) Rb–/– MEF puro cultures or
(d) Rb–/– MEF puro-HsRb cultures. BrdU
incorporation was visualized by FITC staining
(green) and the injected Y13-259 antibody by
TRITC (red). DNA synthesis therefore appears
yellow in injected cells and green in non-
injected cells. 
Table 2
Inhibition of DNA synthesis  in cell lines injected with 
Ras-neutralizing antibody.
Cells % Injected cells in % Inhibition of Mean
DNA synthesis DNA synthesis
Y13-259 IgG Y13-259/IgG
MEF p16–/– 23.9 55.6 57.0
37.5 61.0 38.5 47.7
MEF p21–/– 3.8 71.1 94.6
4.5 66.0 89.0 91.5
MEF Rb+/– 3.4 69.3 95.0
HaCat (Rb+ p16–) 22.4 43.0 47.8
SaOS2 (Rb– p16+) 38.8 47.9 29.0
28.5 48.0 40.0 34.5
C33a (Rb– p16+) 71.0 68.0 < 1.0
J82 (Rb– p16+) 32.0 34.0 6.0
41.9 45.7 8.3 7.0
Asynchronously growing cells were injected with Y13-259 or rat IgG
and processed as described in Table 1.
regulate a much broader range of CDKs. To determine
whether Ras signalling was affected by the loss of CDKIs,
MEFs from p16Ink4–/– and p21Waf1–/– embryos were
microinjected with Y13-259 and the effects on DNA
synthesis measured. Table 2 shows that DNA synthesis in
p16Ink4–/– cells was as resistant to Y13-259 injection as Rb–/–
cells, whereas p21Waf1–/– cells were as sensitive to Y13-259
as cells with wild-type Rb. Furthermore, tumour-derived
cell lines for which loss of pRb or p16 has been demon-
strated (HaCat, SaOS2, C33a and J82) were resistant to
Y13-259 injection to a degree similar to, or higher than,
pRb– or p16– deficient MEFs.
These experiments show that the inactivation of Rb
requires normal Ras function. The experiments with
p16Ink4–/– cells show that a target of Ras-dependent sig-
nalling is the activation of cyclin-D-dependent kinases.
Consistent with these data, previous work has shown that
the introduction of adenovirus E1A protein stimulates DNA
synthesis in cells injected with Y13-259 [13]. E1A com-
plexes with and inactivates Rb, but also has other functions
that include binding to the other ‘pocket’ proteins, p107 and
p130, and to the transcriptional co-regulator p300 [14,15]. 
The comparison of Rb–/– or p16–/– MEFs with wild-type
cells shows that the loss of Rb or p16 confers only partial
resistance to the inhibitory effects of Y13-259, showing that
Rb–/– or p16–/– cells still require some Ras signalling. In con-
trast, DNA synthesis in some tumour cell lines that lack Rb
appears to be completely resistant to injection of Y13-259
(see Table 2 and [16]), suggesting that these tumour cells
have additional genetic alterations that liberate them from
any requirement for Ras function. The residual sensitivity
of MEF Rb–/– and MEF p16–/– cells to Y13-259 injection
could result from p21Ras having multiple functions in cell-
cycle progression. Taylor and Shalloway [17] have recently
shown that, following the early G1 growth-factor-stimu-
lated activation of Ras, there is a later mid-G1 phase of Ras
activation which appears to be independent of extracellular
signal-regulated kinase (ERK) mitogen-activated protein
(MAP) kinase activation, consistent with Ras-dependent
signalling being required at different times in G1 [18]. As
we have injected asynchronously growing cells, Rb–/– or
p16–/– MEFs inhibited by Y13-259 may have been injected
at time points when Ras-dependent function(s) other than
pRb inactivation were required for progression to DNA
synthesis. 
A requirement for Ras activation at several points in the cell
cycle is also consistent with Ras being required for stimula-
tion of several signalling pathways that lead to DNA syn-
thesis, including the ERK MAP kinase pathway and the
phosphatidylinositol 3-kinase pathway [19–21]. Ras-depen-
dent activation of the ERK MAP kinase pathway does seem
to be required for proliferation of Rb–/– MEFs, as we have
observed that DNA synthesis in Rb–/– MEFs is as sensitive
to PD 098059, an inhibitor of the ERK activator MEK [22],
as are Rb+/– cells (S.M., unpublished data).
Acknowledgements
This work was supported by the Cancer Research Campaign (CRC). C.J.M. is
a Gibb life Fellow of the CRC. We are very grateful to David Beach and
Roberto Fahraeus for providing p16–/– MEFs, Tyler Jacks for providing pRb–/–
and pRb+/– embryos and p21Waf1–/– MEFs and to M. Valeri and J. Cordell
(ICR, Sutton, UK) for providing purified Y13-259.
References
1. Mulcahy LS, Smith MR, Stacey DW: Requirement for ras proto-
oncogene function during serum-stimulated growth of NIH 3T3
cells. Nature 1985, 313:241–243.
2. Feig LA, Cooper GM: Inhibition of NIH3T3 cell proliferation by a
mutant ras protein with preferential affinity for GDP. Mol Cell Biol
1988, 8:3235–3243.
3. Adams PD, Kaelin WGJ: Transcriptional control by E2F. Semin
Cancer Biol 1995, 6:99–108.
4. La Thangue NB: DTRF1/E2F: an extending family of heterodimeric
factors implicated in cell cycle control. Trends Biochem Sci 1994,
19:108–114.
5. Sherr CJ: G1 phase progression: cycling on cue. Cell 1994,
79:551–556.
6. Furth ME, Davis LJ, Fleurdelys B, Scolnick EM: Monoclonal antibodies
to the p21 products of the transforming gene of Harvey murine
sarcoma virus and of the cellular ras gene family. J Virol 1982,
43:294–304.
7. Warne PH, Viciana PR, Downward J: Direct interaction of Ras and the
amino-terminal region of Raf-1 in vitro. Nature 1993, 364:352–355.
8. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA:
Effects of an Rb mutation in the mouse. Nature 1992, 359:295–300.
9. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA:
Regulation of retinoblastoma protein functions by ectopic
expression of human cyclins. Cell 1992, 70:993–1006.
10. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato JY, Livingston DM:
Functional interactions of the retinoblastoma protein with
mammalian D-type cyclins. Cell 1993, 73:487–497.
11. Morgan DO: Principles of CDK regulation. Nature 1995,
374:131–134.
12. Sherr CJ: Cancer Cell Cycles. Science 1996, 274:1672–1677.
13. Stacey DW, Dobrowolski SF, Piotrkowski A, Harter ML: The
adenovirus E1A protein overrides the requirement for cellular ras in
initiating DNA synthesis. EMBO J 1994, 13:6107–6114.
14. Nevins JR: Cell targets of the DNA tumor viruses. Curr Opin Genet
Dev 1994, 4:130–134.
15. Jansen-Durr P: How viral oncogenes make the cell cycle. Trends
Genet 1996, 12:270–275.
16. Stacey DW, DeGudicibus SR, Smith MR: Cellular ras activity and
tumor cell proliferation. Exp Cell Res 1987, 171:232–242.
17. Taylor SJ, Shalloway D: Cell cycle-dependent activation of Ras. Curr
Biol 1996, 6:1621-1627.
18. Dobrowoski S, Harter M, Stacey DW: Cellular ras activity is required
for passage through multiple points of the G0–G1 phase in BALB-c
3T3 cells. Mol Cell Biol 1994, 14:5441–5449.
19. Joneson T, White MA, Wigler MH, Bar-Sagi D: Stimulation of
membrane ruffling and MAP kinase activation by distinct effectors
of Ras. Science 1996, 271:810–812.
20. de Vries Smits AMM, Burgering BMT, Leevers SJ, Marshall CJ, Bos JL:
Involvement of p21ras in activation of extracellular signal-regulated
kinase-2. Nature 1992, 357:602–604.
21. Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I,
Fry M, et al.: Phosphatidylinositol-3-OH kinase as a direct target of
Ras. Nature 1994, 370:527–532.
22. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic
inhibitor of the mitogen-activated protein kinase cascade. Proc Natl
Acad Sci USA 1995, 92:7686–7689.
23. Friend SH, Horowitz JM, Gerber MR, Wang XF, Bogenmann E, Li FP,
Weinberg RA: Deletions of a DNA sequence in retinoblastomas and
mesenchymal tumors: organization of the sequence and its
encoded protein. Proc Natl Acad Sci USA 1987, 84:9059–9063.
24. Morgenstern JP, Land H: Advanced mammalian gene transfer: high
titre retroviral vectors with multiple drug selection markers and a
complimentary helper-free packaging cell line. Nucleic Acids Res
1990, 18:3587–3596.
25. Pear W, Nolan G, Scott M, Baltimore D: Production of high-titer
helper-free retroviruses by transient transfection. Proc Natl Acad
Sci USA 1993, 90:8392–8396.
Brief Communication 221
